RT Journal Article
SR Electronic
T1 Real-world effectiveness and durability of dual antiretroviral therapy in HIV-infected patients
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP ejhpharm-2022-003277
DO 10.1136/ejhpharm-2022-003277
A1 Laia Pérez-Cordón
A1 Azhara Sánchez
A1 Sergio Marin
A1 Lluis Force
A1 Mateu Serra-Prat
A1 Elisabet Palomera
A1 Lluis Campins
YR 2022
UL http://ejhp.bmj.com/content/early/2022/07/26/ejhpharm-2022-003277.abstract
AB Background and objectives While randomised controlled trials in HIV-infected patients have shown that certain dual antiretroviral therapy (DAT) regimens are non-inferior in terms of efficacy compared with classical triple-drug regimens, few real clinical experiences have been described. The aim of the study was to investigate, in real clinical practice, DAT effectiveness, durability, and risk factors for treatment discontinuation.Methods This was a prospective cohort study that included HIV-infected patients treated with DAT (2015–2020). DAT was considered effective when patients achieved or maintained virological suppression and was assessed at 24 and 48 weeks. DAT durability was evaluated using the Kaplan-Meier method. Adherence and treatment cost were compared with patients’ previous antiretroviral regimens.Results 51 patients were included, 27.5% with HIV-1 RNA ≥50 copies/mL at baseline, treated with a wide range of dual combinations. At 48 weeks follow-up, 83.8% and 50.0% of patients who started DAT with HIV-1 RNA <50 copies/mL and ≥50 copies/mL, respectively, were suppressed. 39 out of 51 patients (76.5%) maintained DAT for a mean treatment duration of 40.5±14.8 weeks. Full adherence was observed in 78.4% of patients compared with 70.2% in the previous regimen. Mean daily cost was €18.6±4.3 compared with €16.1±7.9 in the previous regimen (p=0.008).Conclusion DAT effectiveness and durability were higher in patients who were virologically suppressed at baseline. DAT is a possible alternative for virologically non-suppressed patients who cannot be treated with a triple-drug regimen.No data are available.